Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201)

According to data from the AGAVE-201 trial presented during the 2023 American Society of Hematology Annual Meeting, heavily pretreated patients with refractory chronic GVHD who were treated with axatilimab experienced robust clinical activity and durable responses in all three dose cohorts: 0.3 mg/kg every 2 weeks, 1 mg/kg every 2 weeks, or 3 mg/kg every 4 weeks. The highest overall response rate and least toxicity was seen at the 0.3 mg/kg every-2-week dose.